Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ | Q05513 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | QPCT | Q16769 | 3/20 | 0.39 |
| ▸ | KIF11 | P52732 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ERO1A | Q96HE7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3596611 | 1.00 | PRKCZ (0.49) | PRKCZTP53MAPTSLC6A3SLC6A2 | |
| SCHEMBL3591136 | 0.93 | PRKCZ (0.44) | PRKCZTP53MAPTSLC6A3SLC6A2 | |
| SCHEMBL3591132 | 0.93 | PRKCZ (0.44) | PRKCZTP53MAPTSLC6A3SLC6A2 | |
| SCHEMBL8789317 | 0.83 | SLC6A3 (0.50) | SLC6A3SLC6A2LMNAQPCTALDH1A1 | |
| SCHEMBL3590816 | 0.81 | MEN1 (0.46) | SLC6A3SLC6A2QPCT | |
| SCHEMBL3590822 | 0.81 | MEN1 (0.46) | SLC6A3SLC6A2QPCT | |
| SCHEMBL3592855 | 0.81 | PRKCZ (0.48) | PRKCZTP53MAPTLMNAQPCT | |
| SCHEMBL3592858 | 0.81 | PRKCZ (0.48) | PRKCZTP53MAPTLMNAQPCT | |
| SCHEMBL14161639 | 0.78 | ALDH1A1 (0.46) | SLC6A3SLC6A2LMNAQPCTALDH1A1 | |
| SCHEMBL3591294 | 0.78 | TNKS2 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130210769-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2013-08-15 | — | — | US | disclosed |
| US-8431607-B2 | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2013-04-30 | — | — | US | disclosed |
| US-20100234365-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2010-09-16 | — | — | US | disclosed |
| CN-101600689-A | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | IRM LLC (VG) | 2009-12-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210769-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | CNR1, CNR2, FAAH | PRKCZ 2082/4885TP53 4640/4885MAPT 1780/4885 |
| US-20100234365-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | CNR1, CNR2, FAAH | PRKCZ 2082/4885TP53 4640/4885MAPT 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.